In regards to patient mortality, the data from the British Society for Rheumatology Biologics Register for RA (BSRBR-RA) suggest that the RA-ILD who were administered rituximab as their initial biologic had superior long-term survival rates when compared to those who began treatment with TNF inhibitors, with an adjusted 5-year risk of mortality in the RTX-treated patients of approximately half that in the TNF inhibitor-treated patients, but the difference was not statistically significant (HR 0.53, 95% CI: 0.26 to 1.10) [52]. The gene discussed is TNF; the disease is interstitial lung disease.